fbpx Yourgene Health plc - Home
previous arrow
next arrow
Slider

Please find below the latest news from Yourgene Health. We also share this news across social media networks.

  • 6 April 2021 - Testing service agreement with MyHealthChecked plc +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Testing service agreement with MyHealthChecked plc

    Yourgene Genomic Services providing COVID-19 services to MHC’s new Boots partnership

    Manchester, UK – 6 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has signed a COVID-19 testing services agreement with its partner MyHealthChecked plc (AIM: MHC) (“MyHealthChecked”) to support their newly announced partnership with Boots UK Limited (“Boots”), the health and beauty retailer and

    Read More
  • 29 March 2021 - COVID-19 update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    COVID-19 update

    Approved provider of day two and day eight coronavirus testing for international arrivals, for both PCR and sequencing

    Manchester, UK – 29 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services COVID-19 testing services have been approved by the Department of Health and Social Care (DHSC). Yourgene has been added to the UK Government’s approved list as a private

    Read More
  • 19 March 2021 - Twin Pregnancy study published using Yourgene’s IONA® Test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Twin Pregnancy study published using Yourgene’s IONA ® Test

    Manchester, UK – 19 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the paper published in the American Journal of Obstetrics and Gynecology by Khalil et al., titled: “Non-invasive Prenatal Screening in Twin Pregnancies with cell-free DNA using the IONA ® Test: a prospective multicentre study.”

    The article details a multicentre study that took place in

    Read More
  • 17 March 2021 - Appointment of VP of Sales North America +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Appointment of VP of Sales North America
    Strategic hire to expand Yourgene’s commercial footprint in North America

    Manchester, UK – 17 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has appointed Scott Sargent as Vice President of Sales North America with immediate effect, to support the Group’s plans to expand and grow its commercial footprint in the North American market, following the

    Read More
  • 11 March 2021 - Yourgene Genomic Services portfolio expansion +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services portfolio expansion

    Cytox’s genoSCORE TM -LAB test can predict the risk of developing Alzheimer’s disease
    Yourgene Genomic Services to run the array-based test at Citylabs 1.0 in Manchester

    Manchester, UK – 11 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services (“YGS”) has signed a contract with Cytox Ltd (“Cytox”), a collaborative partner, to run Cytox’s genetic

    Read More
  • 1 March 2021 - First US Supply Agreement for Coastal Genomics' Technology Signed with Major Strategic Partner +

    Yourgene Health plc


    ("Yourgene" or the "Group" or the "Company")

    First US Supply Agreement for Coastal Genomics’ Technology Signed with Major Strategic Partner

    Manchester, UK – 1 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s wholly-owned US subsidiary, has signed a supply agreement (“the Agreement”) with a large US clinical laboratory group (“the Partner”). The Agreement is worth an estimated $1.5m over five years to Yourgene and

    Read More
  • 22 February 2021 - Partnership with NPH +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Partnership with NPH

    To provide COVID-19 testing service for Leeds Bradford Airport

    Manchester, UK – 22 February 2021:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partnership with Newcastle Premier Health Limited 1 (“NPH”), a leading provider of independent medical services in Newcastle and the North East, will supply COVID-19 PCR testing services to Leeds Bradford Airport from the Company’s laboratory in Manchester.

    Read More
  • 8 February 2021 - Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Trading update

    Strong H2 momentum expected to deliver double-digit annual growth but below expectations

    Deferred revenue opportunities, investment in offering and further new initiatives expected to drive resumption of stronger subsequent growth

    Manchester, UK – 8 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, provides an update on current trading for the second half of the financial year to 31 March 2021 (“H2”).

    Whilst

    Read More
  • 13 January 2021 - DPYD screening recommended in Belgium +

    Yourgene Health plc
    ("Yourgene" or the "Group" or the "Company")

    DPYD screening recommended in Belgium

    Manchester, UK – 13 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the research article published on 11 January 2021, in Acta Clinica Belgica, titled: ‘Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).’

    The research article endorses screening for Dihydropyrimidine Dehydrogenase (DPD) deficiency which can cause severe and sometimes lethal side

    Read More
  • 11 January 2021 - Clarigene® SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19 +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Clarigene® SARS-CoV-2 Product Update
    and Partnerships with CityDoc and ReCoVa-19

    Manchester, UK – 11 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following the Company’s statement on 24 December 2020, regarding the new virus strain (VUI-202012/01 SARS-CoV-2 variant), Yourgene’s wet lab testing is now complete and has confirmed that the performance of the Clarigene ® SARS-CoV-2 assay is not impacted by any currently

    Read More
  • 24 December 2020 - COVID-19 update: approved provider for UK Government and response to new virus strain +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    COVID-19 update: approved provider for UK Government and r esponse to new virus strain

    Manchester, UK – 24 December 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services has been added to the UK Government’s approved COVID-19 private testing providers list for the Test to Release for International Travel scheme introduced on 15 December 2020 (“Test to Release”), and also for

    Read More
  • 17 December 2020 - Half-year Report +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Half-year Report

    Manchester, UK – 17 December 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year report for the six months ended 30 September 2020.

    The results demonstrate the resilience of the Group’s core business during the first few months of the global pandemic, its responsiveness in launching COVID-19 testing solutions rapidly and its

    Read More
  • 2 December 2020 - DPYD kits recommended by NHS England +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DPYD kits recommended by NHS England

    Manchester, UK – 2 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy Statement, published by NHS England, titled: ‘Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies’ recommending the routine availability of DPYD testing prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects.

    Read More
  • 5 November 2020 - Directorate change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate change
    Chief Scientific Officer appointment to drive new product development roadmap

    Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the appointment of Dr. Joanne Mason as Chief Scientific Officer as a director of the Company with immediate effect.

    Dr Mason has been director of Research & Development (non-board position) at Yourgene since joining the Company in December 2019,

    Read More
  • 3 November 2020 - Partnership with Take2 Health Limited +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Partnership with Take2 Health Limited
    Yourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan

    Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its wholly-owned subsidiary, Yourgene Health Taipei, has signed a regional marketing and services agreement (the “Agreement”) with Hong Kong based Take2 Health Limited (“Take2”), to promote Take2’s clinically-validated genomic test for Nasopharyngeal Carcinoma

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen